fluconazole has been researched along with Critical Illness in 81 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Critical Illness: A disease or state in which death is possible or imminent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether Candida glabrata colonization and invasive candidiasis (IC) increased among critically ill surgical patients 3 years after the introduction of fluconazole prophylaxis to a surgical intensive care unit (SICU)." | 9.14 | The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial. ( Colantuoni, EA; Fothergill, AW; Hendrix, CW; Lipsett, PA; Magill, SS; Merz, WG; Shields, CE; Swoboda, SM, 2009) |
| "Two patients, a 77-yr-old man (case 1) with esophageal cancer and a 66-yr-old woman (case 2) with multiple organ failure developed reversible adrenal insufficiency temporally related to the institution and withdrawal of high-dose fluconazole." | 7.71 | Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients. ( Albert, SG; DeLeon, MJ; Silverberg, AB, 2001) |
| "To determine whether Candida glabrata colonization and invasive candidiasis (IC) increased among critically ill surgical patients 3 years after the introduction of fluconazole prophylaxis to a surgical intensive care unit (SICU)." | 5.14 | The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial. ( Colantuoni, EA; Fothergill, AW; Hendrix, CW; Lipsett, PA; Magill, SS; Merz, WG; Shields, CE; Swoboda, SM, 2009) |
| "Prophylactic use of fluconazole in a selected group of mechanically ventilated patients at high risk for infection reduces the incidence of Candida infections, in particular candidemia." | 5.10 | Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. ( Auckenthaler, R; Garbino, J; Hugonnet, S; Lew, DP; Pittet, D; Romand, JA, 2002) |
| ", causing invasive candidiasis and an overall trend towards reduced fluconazole susceptibility." | 4.87 | Pharmacokinetic evaluation of fluconazole in critically ill patients. ( Lipman, J; Peake, SL; Playford, EG; Roberts, JA; Roberts, MS; Sinnollareddy, M, 2011) |
| "Recent clinical trials have documented the clinical efficacy of the echinocandins and the newer triazoles for the management of invasive candidiasis." | 4.84 | Antifungals in the ICU. ( Calandra, T; Eggimann, P; Playford, EG, 2008) |
| "Prophylactic fluconazole administration for prevention of mycoses in SICU patients appears to successfully decrease the rate of these infections, but this strategy does not improve survival." | 4.82 | Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. ( Chung, K; Jackson, WL; Kollef, MH; Shorr, AF; Waterman, PE, 2005) |
| "This study confirms that the use of azoles recommended for candidemia, mostly fluconazole, as a first-line therapy is a reasonable alternative to caspofungin for ICU patients in our institution." | 3.96 | Evaluation of first-line therapies for the treatment of candidemia in ICU patients: A propensity score analysis. ( Argaud, L; Aubrun, F; Bienvenu, AL; Chidiac, C; Fellahi, JL; Friggeri, A; Guerin, C; Guichon, C; Hernu, R; Leboucher, G; Menotti, J; Monard, C; Paulus, S; Piriou, V; Pradat, P; Rimmele, T, 2020) |
| "The objective of this study was to evaluate the impact of the empirical therapy with fluconazole or an echinocandin on 30- and 90-day mortality in critically ill patients with candidemia." | 3.88 | Initial Antifungal Strategy Reduces Mortality in Critically Ill Patients With Candidemia: A Propensity Score-Adjusted Analysis of a Multicenter Study. ( Arias-Verdú, D; Cantón-Bulnes, L; Díaz-Martín, A; Estella, Á; García-Garmendia, JL; Garnacho-Montero, J; Gordón, M; Loza-Vázquez, A; Ramírez, P; Rodríguez-Delgado, M; Rodriguez-Gomez, J; Sierra, R, 2018) |
| "Fluconazole is recommended as first-line treatment in invasive candidiasis in children and infants." | 3.80 | Insufficient fluconazole exposure in pediatric cancer patients and the need for therapeutic drug monitoring in critically ill children. ( Alffenaar, JW; Kosterink, JG; Pereboom, M; Schölvinck, EH; van den Heuvel, ER; van der Elst, KC, 2014) |
| "Fluconazole is the first line of therapy for the management of candidiasis." | 3.77 | The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients. ( Coleman, JJ; Kourkoumpetis, TK; Manolakaki, D; Mylonakis, E; Tampakakis, E; Velmahos, GC; Ziakas, PD, 2011) |
| "We evaluated whether the likelihood of developing invasive candidiasis (IC) differed depending upon the anatomic site of Candida colonization in 182 surgical intensive care unit (SICU) patients who participated in a randomized trial of fluconazole to prevent candidiasis." | 3.73 | The association between anatomic site of Candida colonization, invasive candidiasis, and mortality in critically ill surgical patients. ( Hendrix, CW; Johnson, EA; Lipsett, PA; Magill, SS; Merz, WG; Pelz, RK; Swoboda, SM, 2006) |
| "Two patients, a 77-yr-old man (case 1) with esophageal cancer and a 66-yr-old woman (case 2) with multiple organ failure developed reversible adrenal insufficiency temporally related to the institution and withdrawal of high-dose fluconazole." | 3.71 | Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients. ( Albert, SG; DeLeon, MJ; Silverberg, AB, 2001) |
| " The ECMO circuit can alter drug pharmacokinetics (PK); thus, standard fluconazole dosing may result in suboptimal drug exposures." | 2.80 | Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation. ( Barrett, J; Benjamin, DK; Brouwer, KL; Capparelli, E; Cohen-Wolkowiez, M; Gonzalez, D; Wade, KC; Watt, KM, 2015) |
| "Anidulafungin was effective, safe and well tolerated for the treatment of C/IC in selected groups of ICU patients." | 2.77 | Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. ( Auzinger, G; Borges Sá, M; Dimopoulos, G; Grigoras, I; Kantecki, M; Marček, T; Meersseman, W; Menichetti, F; Miller, PJ; Montravers, P; Pachl, J; Paiva, JA; Ruhnke, M; Sganga, G, 2012) |
| " The bioavailability of enteral fluconazole was 51% +/- 30% in the open abdomen and 63% +/- 19% (p = 0." | 2.73 | Bioavailability of oral fluconazole in critically ill abdominal trauma patients with and without abdominal wall closure: a randomized crossover clinical trial. ( Alzamel, H; Barquist, ES; Block, EF; Collin, G; Gomez-Fein, E; Martinez, O, 2007) |
| "Mean fluconazole levels were above the highest MIC for C albicans and C parapsilosis in all but 5 patients (4%)." | 2.70 | Enteral fluconazole is well absorbed in critically ill surgical patients. ( Hendrix, CW; Lipsett, PA; Merz, W; Pelz, RK; Rinaldi, MG; Swoboda, SM, 2002) |
| "Six critically ill patients with acute renal failure (ARF) and serious fungal infection." | 2.69 | Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. ( Bruch, HP; Iven, H; Martens, T; Muhl, E; Rob, P, 2000) |
| "Fluconazole alone was given to 27 patients, amphotericin B alone to 10, and sequential therapy to 6." | 2.68 | Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. ( Ibáñez-Lucía, P; León-Gil, C; León-Regidor, MA; Martínez-González, J; Nolla-Salas, J; Sitges-Serra, A; Torres-Rodríguez, JM, 1997) |
| "Invasive fungal infections are important causes of morbidity and mortality among critically ill patients." | 2.53 | Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. ( Attanasio, M; Cortegiani, A; Giarratano, A; Maggiore, A; Naro, AR; Raineri, SM; Russotto, V, 2016) |
| " The median loading dose required to achieve the Cmin target appeared to be greater in patients with higher SOFA or GGT level and in patients undergoing renal replacement therapy." | 1.91 | Suboptimal exposure to fluconazole in critically ill patients: Pharmacokinetic analysis and determinants. ( Bienvenu, AL; Goutelle, S; Leboucher, G; Matusik, E; Parant, F; Piriou, V; Pradat, P; Rimmelé, T; Tod, M, 2023) |
| " Nonetheless, there is a lack in pharmacokinetics information for this population, and dosing criteria may vary between healthcare centers." | 1.91 | Model-informed precision dosing of antimicrobial drugs in pediatrics: experiences from a pilot scale program. ( Arriaga-García, FJ; Medellín-Garibay, SE; Milán-Segovia, RDC; Pérez-González, LF; Rodríguez-Báez, AS; Romano-Moreno, S; Velarde-Salcedo, R, 2023) |
| "Although "Candida pneumonia" is rarely being reported in critically ill patients, Candida airway colonization mainly by Candida albicans is common especially among patients with diabetes, malignancies, and kidney disorders." | 1.72 | Clinical impact of Candida respiratory tract colonization and acute lung infections in critically ill patients with COVID-19 pneumonia. ( Amiri, S; Erami, M; Fakhrehi, M; Getso, MI; Hashemi, SJ; Mehri, N; Momen-Heravi, M; Raiesi, O; Raissi, V; Yarahmadi, M, 2022) |
| "Current fluconazole dosing regimens do not achieve adequate early target attainment in critically ill adults, particularly in those who are overweight, have higher creatinine clearance, or are undergoing CRRT." | 1.62 | Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy. ( Day, RO; Marriott, DJE; Norris, RLG; Pang, E; Reuter, SE; Sandaradura, I; Stocker, SL, 2021) |
| " Physiological changes in critically ill patients may affect the exposure of fluconazole, and therefore dosing adjustments might be needed." | 1.62 | Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients. ( Alffenaar, JWC; Boonstra, JM; Kosterink, JGW; Marriott, DJE; Märtson, AG; Sandaradura, I; Touw, DJ; van der Werf, TS; Zijlstra, JG, 2021) |
| "auris colonization/candidemia are similar to other Candida species." | 1.51 | Detection and treatment of Candida auris in an outbreak situation: risk factors for developing colonization and candidemia by this new species in critically ill patients. ( Alastruey-Izquierdo, A; Calabuig, E; Frasquet, J; López-Hontangas, JL; Martínez, H; Mollar, J; Moret, AM; Pemán, J; Ramírez, P; Ruiz-Gaitán, A; Salavert-Lletí, M; Tasias, M; Zaragoza, Ó, 2019) |
| "Although candidemia has been reported globally, little is known about the differences in candidemia episodes between ICU and surgical wards or the correlation between serum biomarkers and mortality from candidemia." | 1.48 | Clinical characteristics and predictors of mortality in patients with candidemia: a six-year retrospective study. ( Cao, J; Jia, X; Li, C; Wu, X; Zhang, L, 2018) |
| "The clinical context of underlying malignancy and hospitalization in ICU may be relevant to the initial management of candidemia." | 1.46 | The risk and clinical outcome of candidemia depending on underlying malignancy. ( Bretagne, S; Desnos-Ollivier, M; Dromer, F; Lortholary, O; Renaudat, C; Sitbon, K, 2017) |
| " We used previously-published fluconazole clearance data and PK data of critically-ill patients with acute kidney injury to develop a PK model with the goal of determining a therapeutic dosing regimen for critically-ill patients receiving PIRRT." | 1.43 | Fluconazole dosing predictions in critically-ill patients receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation approach. ( Gharibian, KN; Mueller, BA, 2016) |
| "Fluconazole is a widely used antifungal agent used to treat Candida spp." | 1.42 | Influence of sustained low-efficiency diafiltration (SLED-f) on interstitial fluid concentrations of fluconazole in a critically ill patient: Use of microdialysis. ( Lipman, J; Peake, SL; Roberts, JA; Roberts, MS; Sinnollareddy, MG, 2015) |
| "Current fluconazole dosing strategies can be described using either standardized doses (800 or 400 mg) or as weight-based dosing recommendations (12 mg/kg loading dose followed by 6 mg/kg maintenance dose)." | 1.40 | Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration. ( Lopez, ND; Phillips, KM, 2014) |
| "Fluconazole was more frequently used in medium size hospitals than in the large ones (60." | 1.38 | [Trends in systemic antifungal use in critically ill patients. Multicenter observational study, 2006-2010]. ( Alvarez-Lerma, F; Gimeno-Costa, R; Gracia-Arnillas, MP; Insausti-Ordeñana, J; López-Pueyo, MJ; Olaechea-Astigarraga, PM; Otal-Entraigas, JJ; Palomar-Martínez, M; Seijas-Betolaza, I, 2012) |
| " We performed Monte Carlo simulations to optimize dosing to appropriate pharmacodynamic endpoints for this population." | 1.37 | Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets. ( Deldot, ME; Kirkpatrick, CM; Lipman, J; Patel, K; Roberts, JA; Tett, SE, 2011) |
| "Anidulafungin as first-line treatment of C/IC appears to be of particular benefit to ICU patients, improving clinical outcomes and possibly decreasing costs, driven by reduced ICU and hospital stay, when compared with fluconazole." | 1.37 | Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients. ( Cartier, S; Chambers, R; Kett, DH; Maschio, M; Reboli, AC; Rotstein, C; Tarallo, M, 2011) |
| "glabrata fungemia were systematically recorded." | 1.36 | Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients. ( Adrie, C; Clec'h, C; Cohen, Y; Gauzit, R; Karoubi, P; Marsepoil, T; Zarka, D, 2010) |
| "The following pharmacokinetic variables for fluconazole were obtained: The mean volume distribution of steady state dosed at 400 mg every 12 h and 800 mg every 24 h were 0." | 1.32 | Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration. ( Gando, S; Hirano, T; Iseki, K; Ishitani, T; Kameue, T; Matsuda, N; Yagasaki, K, 2003) |
| "Fluconazole patients were significantly more likely to have Candida cultured from sites associated with colonization (43% vs 2%; p < 0." | 1.32 | Impact of fluconazole administration on outcomes in critically ill patients. ( Garrelts, JC; Harrison, PB; Schroeder, TR, 2004) |
| "Fluconazole has gained wide use as an antifungal agent because of its efficacy, limited toxicity, and the paucity of reported drug interactions." | 1.29 | Rifampin-fluconazole interaction in critically ill patients. ( Crowe, HM; Nicolau, DP; Nightingale, CH; Quintiliani, R, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (6.17) | 18.2507 |
| 2000's | 28 (34.57) | 29.6817 |
| 2010's | 32 (39.51) | 24.3611 |
| 2020's | 16 (19.75) | 2.80 |
| Authors | Studies |
|---|---|
| Erami, M | 1 |
| Raiesi, O | 1 |
| Momen-Heravi, M | 1 |
| Getso, MI | 1 |
| Fakhrehi, M | 1 |
| Mehri, N | 1 |
| Yarahmadi, M | 1 |
| Amiri, S | 1 |
| Raissi, V | 1 |
| Hashemi, SJ | 1 |
| Wang, B | 1 |
| Wang, Y | 3 |
| Zhang, L | 2 |
| Lu, F | 1 |
| Zhang, M | 1 |
| Xu, Y | 1 |
| Bienvenu, AL | 2 |
| Pradat, P | 2 |
| Matusik, E | 1 |
| Piriou, V | 2 |
| Rimmelé, T | 2 |
| Parant, F | 1 |
| Tod, M | 1 |
| Leboucher, G | 2 |
| Goutelle, S | 1 |
| De Pascale, G | 1 |
| Martin-Loeches, I | 2 |
| Nseir, S | 1 |
| Velarde-Salcedo, R | 1 |
| Pérez-González, LF | 1 |
| Rodríguez-Báez, AS | 1 |
| Arriaga-García, FJ | 1 |
| Milán-Segovia, RDC | 1 |
| Romano-Moreno, S | 1 |
| Medellín-Garibay, SE | 1 |
| Oladele, RO | 1 |
| Ettu, AO | 1 |
| Medugu, N | 1 |
| Habib, A | 1 |
| Egbagbe, E | 1 |
| Osinaike, T | 1 |
| Makanjuola, OB | 1 |
| Ogunbosi, B | 1 |
| Irowa, OO | 1 |
| Ejembi, J | 1 |
| Uwaezuoke, NS | 1 |
| Adeleke, G | 1 |
| Mutiu, B | 1 |
| Ogunsola, F | 1 |
| Rotimi, V | 1 |
| McGuire, TM | 1 |
| Hollingworth, SA | 1 |
| Dong, Y | 2 |
| Van Driel, ML | 1 |
| Guerin, C | 1 |
| Aubrun, F | 1 |
| Fellahi, JL | 1 |
| Friggeri, A | 1 |
| Guichon, C | 1 |
| Hernu, R | 1 |
| Menotti, J | 1 |
| Monard, C | 1 |
| Paulus, S | 1 |
| Chidiac, C | 1 |
| Argaud, L | 1 |
| Muilwijk, EW | 2 |
| de Lange, DW | 1 |
| Schouten, JA | 1 |
| Wasmann, RE | 1 |
| Ter Heine, R | 1 |
| Burger, DM | 1 |
| Colbers, A | 1 |
| Haas, PJ | 1 |
| Verweij, PE | 1 |
| Pickkers, P | 1 |
| Brüggemann, RJ | 1 |
| Kara, E | 1 |
| Bayraktar Ekincioglu, A | 1 |
| Metan, G | 1 |
| Brüggemann, RJM | 1 |
| Boonstra, JM | 2 |
| Märtson, AG | 2 |
| Sandaradura, I | 4 |
| Kosterink, JGW | 2 |
| van der Werf, TS | 2 |
| Marriott, DJE | 4 |
| Zijlstra, JG | 2 |
| Touw, DJ | 2 |
| Alffenaar, JWC | 2 |
| Wojciechowski, J | 1 |
| Day, RO | 2 |
| Stocker, S | 1 |
| Reuter, SE | 2 |
| Norris, RLG | 1 |
| Pang, E | 1 |
| Stocker, SL | 1 |
| Van Daele, R | 1 |
| Debaveye, Y | 1 |
| Lagrou, K | 1 |
| Spriet, I | 1 |
| Papadimitriou-Olivgeris, M | 2 |
| Spiliopoulou, A | 2 |
| Fligou, F | 2 |
| Tsiata, E | 1 |
| Kolonitsiou, F | 1 |
| Nikolopoulou, A | 1 |
| Papamichail, C | 1 |
| Spiliopoulou, I | 2 |
| Marangos, M | 2 |
| Christofidou, M | 2 |
| Lortholary, O | 2 |
| Renaudat, C | 1 |
| Sitbon, K | 1 |
| Desnos-Ollivier, M | 1 |
| Bretagne, S | 1 |
| Dromer, F | 1 |
| Xie, J | 1 |
| Xing, Y | 1 |
| Chen, L | 1 |
| Li, Y | 1 |
| Meng, T | 1 |
| Dong, W | 1 |
| Wang, X | 1 |
| Garnacho-Montero, J | 2 |
| Díaz-Martín, A | 1 |
| Cantón-Bulnes, L | 1 |
| Ramírez, P | 2 |
| Sierra, R | 1 |
| Arias-Verdú, D | 1 |
| Rodríguez-Delgado, M | 1 |
| Loza-Vázquez, A | 1 |
| Rodriguez-Gomez, J | 1 |
| Gordón, M | 1 |
| Estella, Á | 1 |
| García-Garmendia, JL | 1 |
| Jia, X | 1 |
| Li, C | 1 |
| Cao, J | 1 |
| Wu, X | 1 |
| Antonelli, M | 1 |
| Cuenca-Estrella, M | 1 |
| Dimopoulos, G | 3 |
| Einav, S | 1 |
| De Waele, JJ | 2 |
| Kanj, SS | 1 |
| Machado, FR | 1 |
| Montravers, P | 4 |
| Sakr, Y | 1 |
| Sanguinetti, M | 2 |
| Timsit, JF | 4 |
| Bassetti, M | 3 |
| Ruiz-Gaitán, A | 1 |
| Martínez, H | 1 |
| Moret, AM | 1 |
| Calabuig, E | 1 |
| Tasias, M | 1 |
| Alastruey-Izquierdo, A | 1 |
| Zaragoza, Ó | 1 |
| Mollar, J | 1 |
| Frasquet, J | 1 |
| Salavert-Lletí, M | 1 |
| López-Hontangas, JL | 1 |
| Pemán, J | 2 |
| Dreyfuss, D | 1 |
| Ricard, JD | 1 |
| Gaudry, S | 1 |
| Massanet, P | 1 |
| Jung, B | 1 |
| Molinari, N | 1 |
| Villiet, M | 1 |
| Moulaire, V | 1 |
| Roch-Torreilles, I | 1 |
| Jaber, S | 1 |
| Reynes, J | 1 |
| Corne, P | 1 |
| Lopez, ND | 1 |
| Phillips, KM | 1 |
| van der Elst, KC | 1 |
| Pereboom, M | 1 |
| van den Heuvel, ER | 1 |
| Kosterink, JG | 1 |
| Schölvinck, EH | 1 |
| Alffenaar, JW | 1 |
| Manolopoulou, P | 1 |
| Vrettos, T | 1 |
| Dodou, V | 1 |
| Filos, KS | 1 |
| Anastassiou, ED | 1 |
| Chen, SC | 1 |
| Sorrell, TC | 3 |
| Chang, CC | 1 |
| Paige, EK | 1 |
| Bryant, PA | 1 |
| Slavin, MA | 1 |
| Bailly, S | 2 |
| Bouadma, L | 1 |
| Azoulay, E | 2 |
| Orgeas, MG | 1 |
| Adrie, C | 2 |
| Souweine, B | 1 |
| Schwebel, C | 1 |
| Maubon, D | 1 |
| Hamidfar-Roy, R | 1 |
| Darmon, M | 1 |
| Wolff, M | 1 |
| Cornet, M | 1 |
| Sinnollareddy, MG | 2 |
| Roberts, JA | 5 |
| Lipman, J | 4 |
| Akova, M | 1 |
| Kaukonen, KM | 1 |
| Koulenti, D | 1 |
| Martin, C | 1 |
| Rello, J | 1 |
| Rhodes, A | 1 |
| Starr, T | 1 |
| Wallis, SC | 2 |
| Roberts, MS | 2 |
| Peake, SL | 2 |
| Ferreira, D | 1 |
| Grenouillet, F | 1 |
| Blasco, G | 1 |
| Samain, E | 1 |
| Hénon, T | 1 |
| Dussaucy, A | 1 |
| Millon, L | 1 |
| Mercier, M | 1 |
| Pili-Floury, S | 1 |
| Watt, KM | 1 |
| Gonzalez, D | 1 |
| Benjamin, DK | 1 |
| Brouwer, KL | 1 |
| Wade, KC | 1 |
| Capparelli, E | 1 |
| Barrett, J | 1 |
| Cohen-Wolkowiez, M | 1 |
| Leon, C | 1 |
| Leroy, O | 1 |
| Constantin, JM | 1 |
| Dupont, H | 1 |
| Guillemot, D | 1 |
| Mira, JP | 1 |
| Perrigault, PF | 1 |
| Gangneux, JP | 1 |
| Shekar, K | 1 |
| Barnett, AG | 1 |
| Diab, S | 1 |
| Fung, YL | 1 |
| Fraser, JF | 1 |
| van der Geest, PJ | 1 |
| Rijnders, BJ | 1 |
| Vonk, AG | 1 |
| Groeneveld, AB | 1 |
| Cortegiani, A | 1 |
| Russotto, V | 1 |
| Maggiore, A | 1 |
| Attanasio, M | 1 |
| Naro, AR | 1 |
| Raineri, SM | 1 |
| Giarratano, A | 1 |
| Gharibian, KN | 1 |
| Mueller, BA | 1 |
| Playford, EG | 4 |
| Eggimann, P | 1 |
| Calandra, T | 2 |
| Magill, SS | 3 |
| Swoboda, SM | 5 |
| Shields, CE | 1 |
| Colantuoni, EA | 1 |
| Fothergill, AW | 1 |
| Merz, WG | 3 |
| Lipsett, PA | 5 |
| Hendrix, CW | 5 |
| Borges Sá, M | 2 |
| Garnacho Montero, J | 1 |
| Cohen, Y | 1 |
| Karoubi, P | 1 |
| Gauzit, R | 1 |
| Marsepoil, T | 1 |
| Zarka, D | 1 |
| Clec'h, C | 1 |
| Kourkoumpetis, TK | 1 |
| Velmahos, GC | 1 |
| Ziakas, PD | 1 |
| Tampakakis, E | 1 |
| Manolakaki, D | 1 |
| Coleman, JJ | 1 |
| Mylonakis, E | 1 |
| Reboli, AC | 1 |
| Rotstein, C | 1 |
| Kett, DH | 1 |
| Maschio, M | 1 |
| Cartier, S | 1 |
| Chambers, R | 1 |
| Tarallo, M | 1 |
| Sinnollareddy, M | 1 |
| Patel, K | 1 |
| Tett, SE | 1 |
| Deldot, ME | 1 |
| Kirkpatrick, CM | 1 |
| Ruhnke, M | 1 |
| Paiva, JA | 1 |
| Meersseman, W | 1 |
| Pachl, J | 1 |
| Grigoras, I | 1 |
| Sganga, G | 1 |
| Menichetti, F | 1 |
| Auzinger, G | 1 |
| Miller, PJ | 1 |
| Marček, T | 1 |
| Kantecki, M | 1 |
| Olaechea-Astigarraga, PM | 1 |
| Alvarez-Lerma, F | 1 |
| Palomar-Martínez, M | 1 |
| Insausti-Ordeñana, J | 1 |
| López-Pueyo, MJ | 1 |
| Seijas-Betolaza, I | 1 |
| Otal-Entraigas, JJ | 1 |
| Gimeno-Costa, R | 1 |
| Gracia-Arnillas, MP | 1 |
| Garbino, J | 2 |
| Lew, DP | 1 |
| Romand, JA | 1 |
| Hugonnet, S | 1 |
| Auckenthaler, R | 1 |
| Pittet, D | 1 |
| Marchetti, O | 1 |
| Van Saene, HK | 1 |
| Silvestri, L | 1 |
| Petros, A | 1 |
| Viviani, M | 1 |
| de la Cal, MA | 1 |
| Zandstra, DF | 1 |
| Yagasaki, K | 1 |
| Gando, S | 1 |
| Matsuda, N | 1 |
| Kameue, T | 1 |
| Ishitani, T | 1 |
| Hirano, T | 1 |
| Iseki, K | 1 |
| Puthanakit, T | 1 |
| Carson, KA | 1 |
| Salvatori, R | 1 |
| Garrelts, JC | 1 |
| Schroeder, TR | 1 |
| Harrison, PB | 1 |
| Takesue, Y | 1 |
| Liolios, A | 1 |
| Gressens, B | 1 |
| Leonard, I | 1 |
| Coche, E | 1 |
| Hantson, P | 1 |
| Shorr, AF | 2 |
| Chung, K | 1 |
| Jackson, WL | 2 |
| Waterman, PE | 1 |
| Kollef, MH | 2 |
| Webster, AC | 2 |
| Craig, JC | 2 |
| Johnson, EA | 1 |
| Pelz, RK | 3 |
| Zaragoza, R | 1 |
| Santhana Krishnan, SG | 1 |
| Cobbs, RK | 1 |
| Lazarus, DR | 1 |
| Sherner, JH | 1 |
| Morrel, M | 1 |
| Fraser, VJ | 1 |
| Barquist, ES | 1 |
| Gomez-Fein, E | 1 |
| Block, EF | 1 |
| Collin, G | 1 |
| Alzamel, H | 1 |
| Martinez, O | 1 |
| Christensen, S | 1 |
| Buhl, M | 1 |
| Tønnesen, EK | 1 |
| Huang, CT | 1 |
| Leu, HS | 1 |
| Nassoura, Z | 1 |
| Ivatury, RR | 1 |
| Simon, RJ | 1 |
| Jabbour, N | 1 |
| Stahl, WM | 1 |
| Zervos, EE | 1 |
| Bass, SS | 1 |
| Robson, MC | 1 |
| Rosemurgy, AS | 1 |
| Nicolau, DP | 1 |
| Crowe, HM | 1 |
| Nightingale, CH | 1 |
| Quintiliani, R | 1 |
| Nolla-Salas, J | 1 |
| Sitges-Serra, A | 1 |
| León-Gil, C | 1 |
| Martínez-González, J | 1 |
| León-Regidor, MA | 1 |
| Ibáñez-Lucía, P | 1 |
| Torres-Rodríguez, JM | 1 |
| Rocco, TR | 1 |
| Reinert, SE | 1 |
| Simms, HH | 1 |
| Blot, SI | 1 |
| Hoste, EA | 1 |
| Vandewoude, KH | 1 |
| Colardyn, FA | 1 |
| Muhl, E | 1 |
| Martens, T | 1 |
| Iven, H | 1 |
| Rob, P | 1 |
| Bruch, HP | 1 |
| Diener-West, M | 1 |
| Hammond, J | 1 |
| Albert, SG | 1 |
| DeLeon, MJ | 1 |
| Silverberg, AB | 1 |
| Posteraro, B | 1 |
| Valentini, P | 1 |
| Delogu, A | 1 |
| De, RG | 1 |
| Boccacci, S | 1 |
| Nacci, A | 1 |
| Sopo, SM | 1 |
| Ranno, O | 1 |
| Morace, G | 1 |
| Fadda, G | 1 |
| Merz, W | 1 |
| Rinaldi, MG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of a Clinical Decision Support System for the Treatment of Invasive Fungal Infections[NCT05656157] | 100 participants (Anticipated) | Observational | 2022-12-01 | Active, not recruiting | |||
| Pharmacokinetics of Fluconazole Given Intravenously as Prophylaxis or Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit (PACIFIC)[NCT02666716] | 20 participants (Actual) | Observational | 2015-05-31 | Completed | |||
| Fluconazole Exposure in Critically Ill Patients and the Value of Therapeutic Drug Monitoring[NCT02491151] | 50 participants (Actual) | Observational | 2014-10-31 | Completed | |||
| Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment (The CANTREAT Study): A Prospective, Randomized, Double Blind, Placebo Controlled Pilot Study[NCT00934934] | Phase 2 | 61 participants (Actual) | Interventional | 2010-04-30 | Terminated (stopped due to slow enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Sequential organ failure assessment. 0-24 The higher the number the more severe organ failure (NCT00934934)
Timeframe: post randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 5.9 |
| Antifungal | 5.9 |
Number of days free of antibiotic use within the first 28 days (NCT00934934)
Timeframe: 28 days
| Intervention | days (Median) |
|---|---|
| Placebo | 16 |
| Antifungal | 10 |
(NCT00934934)
Timeframe: 28 days
| Intervention | pg/ml (Mean) |
|---|---|
| VAP withCandida | 116 |
| VAP Without Candida | 129.1 |
(NCT00934934)
Timeframe: 28 days
| Intervention | mg/l (Mean) |
|---|---|
| VAP withCandida | 133 |
| VAP Without Candida | 145.7 |
Measure of the duration of participant stay in the ICU (NCT00934934)
Timeframe: 28 days
| Intervention | days (Median) |
|---|---|
| Placebo | 11.5 |
| Antifungal | 13 |
Measure of the duration of the participant's hospital stay (NCT00934934)
Timeframe: 90 days
| Intervention | days (Median) |
|---|---|
| Placebo | 29 |
| Antifungal | 28 |
Number of days free of ICU (NCT00934934)
Timeframe: 28 days
| Intervention | days (Median) |
|---|---|
| Placebo | 14 |
| Antifungal | 4 |
(NCT00934934)
Timeframe: 28 days
| Intervention | pg/ml (Mean) |
|---|---|
| VAP withCandida | 97.5 |
| VAP Without Candida | 3 |
Overall recruitment rate per site (NCT00934934)
Timeframe: 32 months
| Intervention | participants per site /month (Number) |
|---|---|
| Overall | 0.6 |
(NCT00934934)
Timeframe: 28 days
| Intervention | ng/ml (Mean) |
|---|---|
| VAP withCandida | 3.0 |
| VAP Without Candida | 22.5 |
Number of days in ICU free of ventilation (NCT00934934)
Timeframe: 28 days
| Intervention | days (Median) |
|---|---|
| Placebo | 8 |
| Antifungal | 9 |
13 reviews available for fluconazole and Critical Illness
| Article | Year |
|---|---|
Antifungal agents for invasive candidiasis in non-neutropenic critically ill adults: What do the guidelines recommend?
Topics: Antifungal Agents; Candidiasis, Invasive; Critical Illness; Echinocandins; Fluconazole; Humans; Prac | 2019 |
Choosing Optimal Antifungal Agents To Prevent Fungal Infections in Nonneutropenic Critically Ill Patients: Trial Sequential Analysis, Network Meta-analysis, and Pharmacoeconomic Analysis.
Topics: Antifungal Agents; Caspofungin; Cost-Benefit Analysis; Critical Illness; Echinocandins; Economics, P | 2017 |
Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014.
Topics: Adolescent; Adult; Antifungal Agents; Candidiasis, Invasive; Child; Child, Preschool; Consensus; Cri | 2014 |
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.
Topics: Adult; Amphotericin B; Antifungal Agents; Critical Illness; Fluconazole; Humans; Immunocompromised H | 2016 |
Antifungals in the ICU.
Topics: Antifungal Agents; Candida; Candidiasis; Critical Illness; Echinocandins; Fluconazole; Humans; Inten | 2008 |
[Role of anidulafungin in critically ill patients].
Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candidiasis; Clinical Trials as Topic; Critical Il | 2008 |
Pharmacokinetic evaluation of fluconazole in critically ill patients.
Topics: Antifungal Agents; Candidiasis; Candidiasis, Invasive; Critical Illness; Drug Evaluation; Fluconazol | 2011 |
[Strategy for the treatment of fungal infections in critically ill surgical patients].
Topics: beta-Glucans; Candidiasis; Critical Illness; Fluconazole; Humans | 2004 |
Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis.
Topics: Antifungal Agents; Candidiasis; Critical Illness; Double-Blind Method; Drug Resistance, Fungal; Drug | 2005 |
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.
Topics: Adult; Amphotericin B; Antifungal Agents; Critical Illness; Fluconazole; Humans; Immunocompromised H | 2006 |
Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials.
Topics: Adult; Antifungal Agents; Critical Illness; Fluconazole; Humans; Immunocompromised Host; Incidence; | 2006 |
Invasive fungal infections in critically ill patients: different therapeutic options and a uniform strategy.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Critical Illness; Cross Infection; Deoxycholic Acid; | 2006 |
[Prophylactic antifungal treatment in critically ill patients. A survey of a Cochrane review].
Topics: Adult; Antifungal Agents; Critical Illness; Evidence-Based Medicine; Fluconazole; Humans; Immunocomp | 2008 |
13 trials available for fluconazole and Critical Illness
| Article | Year |
|---|---|
Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation.
Topics: Administration, Intravenous; Adolescent; Antifungal Agents; Body Weight; Candidiasis, Invasive; Chil | 2015 |
The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial.
Topics: Academic Medical Centers; Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Candida gla | 2009 |
Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Candida; Candidiasis, Invasive; Cr | 2012 |
Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination.
Topics: Aged; Antibiotic Prophylaxis; Antifungal Agents; Candidiasis; Chi-Square Distribution; Critical Illn | 2002 |
Comment on "Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients," by Garbino et al.
Topics: Antifungal Agents; Candidiasis; Critical Illness; Fluconazole; Humans; Neutropenia; Placebos; Risk F | 2003 |
Impact of fluconazole prophylaxis on cortisol levels in critically ill surgical patients.
Topics: Adrenal Gland Diseases; Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antifungal Agents; C | 2004 |
Fluconazole prophylaxis for critically ill patients at high risk for Candida infection.
Topics: Antifungal Agents; Candidiasis; Critical Illness; Fluconazole; Fungemia; Humans | 2005 |
Bioavailability of oral fluconazole in critically ill abdominal trauma patients with and without abdominal wall closure: a randomized crossover clinical trial.
Topics: Abdominal Injuries; Abdominal Wall; Administration, Oral; Adult; Antifungal Agents; Area Under Curve | 2007 |
Candiduria as an early marker of disseminated infection in critically ill surgical patients: the role of fluconazole therapy.
Topics: Adult; Aged; Amphotericin B; Bacterial Infections; Candidiasis; Cause of Death; Colony Count, Microb | 1993 |
Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; APACHE; Candidiasis; | 1997 |
Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole.
Topics: Acute Kidney Injury; Aged; Antifungal Agents; Area Under Curve; Bronchoalveolar Lavage Fluid; Candid | 2000 |
Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients.
Topics: Aged; Antifungal Agents; APACHE; Candidiasis; Critical Illness; Double-Blind Method; Female; Flucona | 2001 |
Enteral fluconazole is well absorbed in critically ill surgical patients.
Topics: Absorption; Adult; Aged; Aged, 80 and over; Antifungal Agents; Critical Illness; Female; Fluconazole | 2002 |
55 other studies available for fluconazole and Critical Illness
| Article | Year |
|---|---|
Clinical impact of Candida respiratory tract colonization and acute lung infections in critically ill patients with COVID-19 pneumonia.
Topics: Amphotericin B; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candidiasis; Caspofu | 2022 |
Surveillance Study of Epidemiology, Antifungal Susceptibility and Risk Factors of Invasive Candidiasis in Critically ill Patients.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Candidiasis, Invasive; Critical Illness; Dr | 2022 |
Suboptimal exposure to fluconazole in critically ill patients: Pharmacokinetic analysis and determinants.
Topics: Adolescent; Adult; Antifungal Agents; Cohort Studies; Critical Illness; Fluconazole; Humans | 2023 |
Antifungal stewardship in critically ill patients.
Topics: Antifungal Agents; Critical Illness; Fluconazole; Humans; Immunocompromised Host | 2023 |
Model-informed precision dosing of antimicrobial drugs in pediatrics: experiences from a pilot scale program.
Topics: Anti-Bacterial Agents; Bayes Theorem; Child; Clindamycin; Critical Illness; Fluconazole; Humans; Lin | 2023 |
Antibiotic Guidelines for Critically Ill Patients in Nigeria.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Clavulanic Acid; Community-Acqu | 2023 |
Evaluation of first-line therapies for the treatment of candidemia in ICU patients: A propensity score analysis.
Topics: Aged; Antifungal Agents; Candidemia; Caspofungin; Cohort Studies; Critical Illness; Female; Fluconaz | 2020 |
Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink Dosing.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Candidiasis; Continuous Renal Replacement The | 2020 |
Might Confounding Factors Have an Effect on Suboptimal Dosing of Fluconazole in Critically Ill Patients?
Topics: Antifungal Agents; Critical Illness; Fluconazole; Humans; Microbial Sensitivity Tests | 2021 |
Reply to Kara et al., "Might Confounding Factors Have an Effect on Suboptimal Dosing of Fluconazole in Critically Ill Patients?"
Topics: Antifungal Agents; Critical Illness; Fluconazole; Humans; Microbial Sensitivity Tests | 2021 |
Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients.
Topics: Adult; Anti-Bacterial Agents; Candidiasis, Invasive; Critical Illness; Fluconazole; Humans; Microbia | 2021 |
Model-Optimized Fluconazole Dose Selection for Critically Ill Patients Improves Early Pharmacodynamic Target Attainment without the Need for Therapeutic Drug Monitoring.
Topics: Adult; Candidiasis, Invasive; Critical Illness; Drug Monitoring; Echinocandins; Fluconazole; Humans | 2021 |
Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy.
Topics: Antifungal Agents; Candida; Candidemia; Critical Illness; Dose-Response Relationship, Drug; Drug Mon | 2021 |
Reply to Van Daele et al., "Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets?"
Topics: Candidiasis, Invasive; Critical Illness; Fluconazole; Humans | 2021 |
Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets?
Topics: Candidiasis, Invasive; Critical Illness; Fluconazole; Humans | 2021 |
Risk factors for isolation of fluconazole and echinocandin non-susceptible
Topics: Antifungal Agents; Candida; Candidiasis; Critical Illness; Drug Resistance, Fungal; Fluconazole; Gre | 2021 |
The risk and clinical outcome of candidemia depending on underlying malignancy.
Topics: Adult; Aged; Antifungal Agents; Candida; Candidemia; Critical Illness; Female; Fluconazole; Humans; | 2017 |
Initial Antifungal Strategy Reduces Mortality in Critically Ill Patients With Candidemia: A Propensity Score-Adjusted Analysis of a Multicenter Study.
Topics: Aged; Antifungal Agents; Candida; Candidemia; Critical Illness; Echinocandins; Female; Fluconazole; | 2018 |
Clinical characteristics and predictors of mortality in patients with candidemia: a six-year retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antifungal Agents; Candida; Candi | 2018 |
ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients.
Topics: Antifungal Agents; Candidiasis, Invasive; Critical Illness; Delphi Technique; Disease Management; Ec | 2019 |
Detection and treatment of Candida auris in an outbreak situation: risk factors for developing colonization and candidemia by this new species in critically ill patients.
Topics: Adult; Aged; Antifungal Agents; Candida; Candidemia; Case-Control Studies; Critical Illness; Disease | 2019 |
Amphotericin B deoxycholate for candidiasis in intensive care unit patients revisited: medical, ethical, and financial implications.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Creatinine; Critical Illness; Cross Infection; Deoxy | 2013 |
EPICO PROJECT. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non- neutropenic critically ill adult patients.
Topics: Antifungal Agents; Candida; Candidiasis, Invasive; Consensus; Critical Illness; Delphi Technique; Ec | 2013 |
[Antifungal treatment for suspected or proved candidiasis in the critically ill].
Topics: Adult; Aged; Antifungal Agents; Candida albicans; Candidiasis; Critical Illness; Drug Utilization; E | 2014 |
Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration.
Topics: Antifungal Agents; Area Under Curve; Critical Illness; Drug Monitoring; Fluconazole; Half-Life; Hemo | 2014 |
Insufficient fluconazole exposure in pediatric cancer patients and the need for therapeutic drug monitoring in critically ill children.
Topics: Adolescent; Antifungal Agents; Candidiasis; Child; Child, Preschool; Critical Illness; Drug Monitori | 2014 |
Association of KPC-producing Klebsiella pneumoniae colonization or infection with Candida isolation and selection of non-albicans species.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; beta-Lactamases; Candida; Candidiasis; Carrier St | 2014 |
Failure of empirical systemic antifungal therapy in mechanically ventilated critically ill patients.
Topics: Aged; Antifungal Agents; Candidiasis, Invasive; Critical Illness; Databases, Factual; Female; Flucon | 2015 |
Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.
Topics: Aged; Anidulafungin; Antifungal Agents; Caspofungin; Critical Illness; Drug Monitoring; Echinocandin | 2015 |
Influence of sustained low-efficiency diafiltration (SLED-f) on interstitial fluid concentrations of fluconazole in a critically ill patient: Use of microdialysis.
Topics: Adult; Antifungal Agents; Chromatography; Critical Illness; Extracellular Fluid; Fluconazole; HIV In | 2015 |
Outcomes associated with routine systemic antifungal therapy in critically ill patients with Candida colonization.
Topics: Adult; Aged; Antifungal Agents; Candida; Candidiasis; Critical Care Outcomes; Critical Illness; Cros | 2015 |
Are prophylactic antifungals in highly colonized patients safe and effective?
Topics: Antifungal Agents; Candida; Candidiasis; Critical Illness; Female; Fluconazole; Humans; Male | 2015 |
Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data.
Topics: Aged; Antifungal Agents; Candidiasis, Invasive; Comorbidity; Critical Illness; Disease Progression; | 2015 |
Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models.
Topics: Animals; Anti-Infective Agents; Carbapenems; Caspofungin; Ceftriaxone; Ciprofloxacin; Critical Illne | 2015 |
Echinocandin to fluconazole step-down therapy in critically ill patients with invasive, susceptible Candida albicans infections.
Topics: Administration, Intravenous; Adult; Aged; Anidulafungin; Antifungal Agents; Candidiasis, Invasive; C | 2016 |
Fluconazole dosing predictions in critically-ill patients receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation approach.
Topics: Acute Kidney Injury; Antifungal Agents; Area Under Curve; Candidiasis; Computer Simulation; Critical | 2016 |
Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients.
Topics: Adult; Aged; Antifungal Agents; Candida glabrata; Candidiasis; Cohort Studies; Critical Care; Critic | 2010 |
The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Candida; Candidiasis; Critical Illness; Drug Resi | 2011 |
Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.
Topics: Adult; Aged; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Clinical Trials, P | 2011 |
Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.
Topics: Aged; Antifungal Agents; Anuria; Critical Illness; Dose-Response Relationship, Drug; Drug Administra | 2011 |
[Trends in systemic antifungal use in critically ill patients. Multicenter observational study, 2006-2010].
Topics: Amphotericin B; Antifungal Agents; Caspofungin; Community-Acquired Infections; Critical Illness; Cro | 2012 |
Antifungal prophylaxis for intensive care unit patients: let's fine tune it.
Topics: Antifungal Agents; Candidiasis; Critical Illness; Cross Infection; Fluconazole; Humans; Intensive Ca | 2002 |
Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration.
Topics: Adult; Aged; Antifungal Agents; Critical Illness; Female; Fluconazole; Hemodiafiltration; Humans; Ma | 2003 |
Impact of fluconazole administration on outcomes in critically ill patients.
Topics: Adult; Antifungal Agents; Candida; Candidiasis; Case-Control Studies; Critical Illness; Female; Fluc | 2004 |
Candida albicans lung abscess sensitive to fluconazole and responding only to amphotericin B in a non-immunocompromised critically ill patient.
Topics: Amphotericin B; Antifungal Agents; Candida albicans; Candidiasis; Critical Illness; Fluconazole; Hum | 2005 |
The association between anatomic site of Candida colonization, invasive candidiasis, and mortality in critically ill surgical patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; APACHE; Candida; Candidiasis; Critica | 2006 |
Reversible acute adrenal insufficiency caused by fluconazole in a critically ill patient.
Topics: Acute Disease; Adrenal Insufficiency; Adult; Antifungal Agents; Critical Illness; Fluconazole; Human | 2006 |
Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Cand | 2007 |
Candiduria as an early marker of disseminated infection in critically ill surgical patients.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Critical Illness; Fluconazole; Humans; Surg | 1995 |
Fluconazole increases bactericidal activity of neutrophils.
Topics: Antifungal Agents; Blood Bactericidal Activity; Critical Illness; Escherichia coli; Fluconazole; Hum | 1996 |
Rifampin-fluconazole interaction in critically ill patients.
Topics: Adult; Anti-Bacterial Agents; Antifungal Agents; Biological Availability; Critical Illness; Drug Int | 1995 |
Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance.
Topics: Antifungal Agents; Bacterial Infections; Candidiasis; Case-Control Studies; Cohort Studies; Critical | 2000 |
Inadequate proof of adverse outcome due to the use of fluconazole in critically ill patients.
Topics: Antifungal Agents; APACHE; Bacterial Infections; Candidiasis; Critical Illness; Drug Resistance, Mic | 2000 |
Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients.
Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Aged; Antifungal Agents; Candidiasis; Cosyntropi | 2001 |
Candida albicans endocarditis diagnosed by PCR-based molecular assay in a critically ill pediatric patient.
Topics: Antifungal Agents; Candida albicans; Candidiasis; Child, Preschool; Critical Illness; Down Syndrome; | 2002 |